Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

Table 3 Pre-treatment prognostic factors for survival in hepatic arterial infusion chemotherapy treatment

Variables	Univariate	Multivariate1
	HR (95%CI)	HR (95%CI)	P-value
Age (< 60/≥ 60 yr)	0.991 (0.514-1.912)
Gender (male/female)	1.453 (0.687-3.076)
Maximal tumor size (< 10/≥ 10 cm)	1.693 (0.894-3.204)
Tumor volume (< 400/≥ 400 cm3)	2.509 (1.289-4.885)	2.520 (1.252-5.072)	0.01
Child-Pugh score (5/> 5)	2.099 (1.038-4.244)	1.812 (0.878-3.738)	0.108
Stage
mUICC stage (III/IV)	1.198 (0.502-2.863)
AJCC (III/IV)	2.133 (1.085-4.193)	1.803 (0.895-3.634)	0.099
Extrahepatic metastases	1.508 (0.772-2.948)
Pre-HAIC treatment	0.939 (0.503-1.755)
Portal vein thrombosis (Vp4 vs non-Vp4)	1.603 (0.829-3.100)
AFP level (< 200/≥ 200 ng/mL)	1.707 (0.845-3.448)
PIVKA-II (< 40/≥ 40 mAU/mL)	2.860 (1.110-7.368)	3.121 (1.177-8.274)	0.022

¹Those variables with P < 0.05 in univariate analysis were included. AFP: Alpha-fetoprotein; AJCC: American Joint Committee on Cancer; HAIC: Hepatic arterial infusion chemotherapy; PIVKA: Protein induced by vitamin K absence or antagonist; mUICC: Modified Union for International Cancer Control.